Home LiteratureArticle Details
PMID: 2278545 Published · ppublish English Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.

A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.

The New England journal of medicine ·Vol. 322 ·No. 20 ·1990-05-17 ·Pages 1405-11

Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J

Abstract

Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. We evaluated the efficacy and safety of methylprednisolone and naloxone in a multicenter randomized, double-blind, placebo-controlled trial in patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury. Methylprednisolone was given to 162 patients as a bolus of 30 mg per kilogram of body weight, followed by infusion at 5.4 mg per kilogram per hour for 23 hours. Naloxone was given to 154 patients as a bolus of 5.4 mg per kilogram, followed by infusion at 4.0 mg per kilogram per hour for 23 hours. Placebos were given to 171 patients by bolus and infusion. Motor and sensory functions were assessed by systematic neurological examination on admission and six weeks and six months after injury. After six months the patients who were treated with methylprednisolone within eight hours of their injury had significant improvement as compared with those given placebo in motor function (neurologic change scores of 16.0 and 11.2, respectively; P = 0.03) and sensation to pinprick (change scores of 11.4 and 6.6; P = 0.02) and touch (change scores, 8.9 and 4.3; P = 0.03). Benefit from methylprednisolone was seen in patients whose injuries were initially evaluated as neurologically complete, as well as in those believed to have incomplete lesions. The patients treated with naloxone, or with methylprednisolone more than eight hours after their injury, did not differ in their neurologic outcomes from those given placebo. Mortality and major morbidity were similar in all three groups. We conclude that in patients with acute spinal-cord injury, treatment with methylprednisolone in the dose used in this study improves neurologic recovery when the medication is given in the first eight hours. We also conclude that treatment with naloxone in the dose used in this study does not improve neurologic recovery after acute spinal-cord injury.

MeSH Terms
Acute Disease Adolescent Adult Double-Blind Method Female Humans Infusions, Intravenous Injections, Intravenous Male Methylprednisolone/administration & dosage,therapeutic use Middle Aged Motor Activity Multicenter Studies as Topic Naloxone/administration & dosage,therapeutic use Randomized Controlled Trials as Topic Sensation Spinal Cord Injuries/drug therapy,physiopathology Time Factors
Chemicals
Naloxone Methylprednisolone
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Bracken M B
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510.
Shepard M J
Collins W F
Holford T R
Young W
Baskin D S
Eisenberg H M
Flamm E
Leo-Summers L
Maroon J
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
0028-4793
Published
1990-05-17
Pages
1405-11
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Grants
NINDS NIH HHS · NS-15078 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com